SYSNAV
21
11
15
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
4.8%
1 terminated/withdrawn out of 21 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Role: collaborator
Study to Evaluate the Feasibility of Syde® Digital Endpoints for Monitoring Patients With Progressive Supranuclear Palsy - Richardson Syndrome (PSP-R)
Role: lead
Natural History Study for Patients With Nemaline Myopathy in Belgium
Role: collaborator
Pilot Study to Identify and Validate Digital Biomarkers in Osteoarthritis of the Knee
Role: collaborator
Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis
Role: lead
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
Role: lead
Prospective Longitudinal Multicentric Study to Evaluate Syde® Digital Endpoints in Healthy Adults
Role: lead
Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn Screening
Role: collaborator
Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis
Role: lead
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
Role: collaborator
Gait Analysis Parameter and Upper Limb Evaluation in Control Participants
Role: collaborator
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Role: collaborator
Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Role: collaborator
Natural History Study for Patients With Angelman Syndrome
Role: collaborator
Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.
Role: collaborator
Holter of Movement in Patients with Multiple Sclerosis in Controlled Environment.
Role: collaborator
Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
Role: collaborator
Holter of Movement in Patients with Multiple Sclerosis in Uncontrolled Environment.
Role: collaborator
Controlled Study of Upper and Lower Limb Movements in Patients Patients with Pathologies That Have an Impact on Ambulation or Motor Function
Role: collaborator
Holter of Movement in Patients with SMA Undergoing Treatment.
Role: collaborator